BioCentury | Mar 2, 2018
Clinical News

Sumitomo's transdermal blonanserin meets in Phase III for schizophrenia

...dopamine D2 and serotonin receptor 2A (5-HT2A; HT2RA) antagonist, that uses transdermal formulation technology from Nitto Denko Corp....
...Tokyo:6988). Sumitomo markets an oral formulation of blonanserin as Lonasen in Japan to treat schizophrenia. Nitto Denko Corp....
...score at week six Status: Phase III data Milestone: Submit NDA (mid-2018) Jaime De Leon blonanserin patch Lonasen patch Nitto Denko Corp. Sumitomo...
BioCentury | Nov 19, 2016
Strategy

Adding on in fibrosis

...Bristol-Myers Squibb Co. ’s deal to license worldwide rights to Nitto Denko Corp .’s antifibrotic siRNA therapy...
...clade H member 1 (SERPINH1; Hsp47) Fibrosis due to NASH or HCV Ph Ib 2H17 Nitto Denko Corp....
...City, Calif. Miyazaki Hospital, Miyazaki, Japan Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan Nitto Denko Corp....
BioCentury | Nov 11, 2016
Company News

Nitto, Bristol-Myers deal

...is eligible for undisclosed option exercise payments. BMS said the option is not time limited. Nitto Denko Corp....
...Tokyo:6988), Osaka, Japan Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y Business: Hepatic Meghan Sullivan ND-L02-s0201 Bristol Myers Squibb Co. Nitto Denko Corp. Hsp47...
BioCentury | Nov 10, 2016
Company News

BMS's NASH portfolio grows via deal for Nitto's siRNA

...Y420 to Y7,262 on Thursday. The partners announced the deal after market close in Japan. Meghan Sullivan ND-L02-s0201 Nitto Denko Corp. Bristol...
BioCentury | Dec 7, 2015
Clinical News

ND-L02-s0201 regulatory update

...SERPINH1 ; Hsp47 ) is in Phase Ib/II testing to treat patients with liver fibrosis. Nitto Denko Corp....
BioCentury | Sep 23, 2013
Company News

Astellas, Toa Eiyo sales and marketing update

...patch and ¥123 ($1.24) for the 8 mg patch. The patch, which was co-developed by Nitto Denko Corp....
BioCentury | Jul 15, 2013
Clinical News

Bisono Tape regulatory update

...and Welfare (MHLW) approved once-daily Bisono Tape transdermal patch from Toa Eiyo to treat hypertension. Nitto Denko...
...contains 4 or 8 mg of adrenergic receptor beta 1 ( ADRB1 ) blocker bisoprolol. Nitto Denko...
...Tokyo, Japan) will market it in Japan. Toa Eiyo and Astellas will co-promote the product. Nitto Denko Corp....
BioCentury | Feb 14, 2011
Company News

Avecia, Nitto Denko deal

...division, provides contract manufacturing services. Further details were not disclosed. Avecia Ltd. , Manchester, U.K. Nitto Denko Corp....
BioCentury | Jul 26, 2010
Company News

Nitto Denko, Quark deal

...therapeutics to treat fibrotic diseases. The therapeutics will be developed using Quark's RNAi technologies and Nitto Denko's...
...will have rights to commercialize therapeutics developed under the deal. Further terms were not disclosed. Nitto Denko Corp....
BioCentury | Nov 14, 2005
Company News

BioDelivery, Nitto Denko deal

...expects to start Phase III trials this quarter. BioDelivery Sciences International Inc. (BDSI), Morrisville, N.C. Nitto Denko Corp....
Items per page:
1 - 10 of 13
BioCentury | Mar 2, 2018
Clinical News

Sumitomo's transdermal blonanserin meets in Phase III for schizophrenia

...dopamine D2 and serotonin receptor 2A (5-HT2A; HT2RA) antagonist, that uses transdermal formulation technology from Nitto Denko Corp....
...Tokyo:6988). Sumitomo markets an oral formulation of blonanserin as Lonasen in Japan to treat schizophrenia. Nitto Denko Corp....
...score at week six Status: Phase III data Milestone: Submit NDA (mid-2018) Jaime De Leon blonanserin patch Lonasen patch Nitto Denko Corp. Sumitomo...
BioCentury | Nov 19, 2016
Strategy

Adding on in fibrosis

...Bristol-Myers Squibb Co. ’s deal to license worldwide rights to Nitto Denko Corp .’s antifibrotic siRNA therapy...
...clade H member 1 (SERPINH1; Hsp47) Fibrosis due to NASH or HCV Ph Ib 2H17 Nitto Denko Corp....
...City, Calif. Miyazaki Hospital, Miyazaki, Japan Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan Nitto Denko Corp....
BioCentury | Nov 11, 2016
Company News

Nitto, Bristol-Myers deal

...is eligible for undisclosed option exercise payments. BMS said the option is not time limited. Nitto Denko Corp....
...Tokyo:6988), Osaka, Japan Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y Business: Hepatic Meghan Sullivan ND-L02-s0201 Bristol Myers Squibb Co. Nitto Denko Corp. Hsp47...
BioCentury | Nov 10, 2016
Company News

BMS's NASH portfolio grows via deal for Nitto's siRNA

...Y420 to Y7,262 on Thursday. The partners announced the deal after market close in Japan. Meghan Sullivan ND-L02-s0201 Nitto Denko Corp. Bristol...
BioCentury | Dec 7, 2015
Clinical News

ND-L02-s0201 regulatory update

...SERPINH1 ; Hsp47 ) is in Phase Ib/II testing to treat patients with liver fibrosis. Nitto Denko Corp....
BioCentury | Sep 23, 2013
Company News

Astellas, Toa Eiyo sales and marketing update

...patch and ¥123 ($1.24) for the 8 mg patch. The patch, which was co-developed by Nitto Denko Corp....
BioCentury | Jul 15, 2013
Clinical News

Bisono Tape regulatory update

...and Welfare (MHLW) approved once-daily Bisono Tape transdermal patch from Toa Eiyo to treat hypertension. Nitto Denko...
...contains 4 or 8 mg of adrenergic receptor beta 1 ( ADRB1 ) blocker bisoprolol. Nitto Denko...
...Tokyo, Japan) will market it in Japan. Toa Eiyo and Astellas will co-promote the product. Nitto Denko Corp....
BioCentury | Feb 14, 2011
Company News

Avecia, Nitto Denko deal

...division, provides contract manufacturing services. Further details were not disclosed. Avecia Ltd. , Manchester, U.K. Nitto Denko Corp....
BioCentury | Jul 26, 2010
Company News

Nitto Denko, Quark deal

...therapeutics to treat fibrotic diseases. The therapeutics will be developed using Quark's RNAi technologies and Nitto Denko's...
...will have rights to commercialize therapeutics developed under the deal. Further terms were not disclosed. Nitto Denko Corp....
BioCentury | Nov 14, 2005
Company News

BioDelivery, Nitto Denko deal

...expects to start Phase III trials this quarter. BioDelivery Sciences International Inc. (BDSI), Morrisville, N.C. Nitto Denko Corp....
Items per page:
1 - 10 of 13